News
Boehringer Ingelheim is continuing to explore its newfound interest in eye health, penning a $1 billion biobucks pact with Re-Vana Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback